<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>Zepbound on GLP-1 指南 — Ozempic、Wegovy、Mounjaro 循证解读</title><link>https://glp1decode.com/zh/tags/zepbound/</link><description>Recent content in Zepbound on GLP-1 指南 — Ozempic、Wegovy、Mounjaro 循证解读</description><image><title>GLP-1 指南 — Ozempic、Wegovy、Mounjaro 循证解读</title><url>https://glp1decode.com/images/default-og.png</url><link>https://glp1decode.com/images/default-og.png</link></image><generator>Hugo</generator><language>zh</language><lastBuildDate>Sat, 04 Jul 2026 00:00:00 +0000</lastBuildDate><atom:link href="https://glp1decode.com/zh/tags/zepbound/index.xml" rel="self" type="application/rss+xml"/><item><title>Zepbound 减肥：临床试验实际显示了什么</title><link>https://glp1decode.com/zh/posts/zepbound-tirzepatide-weight-loss-2026/</link><pubDate>Sat, 04 Jul 2026 00:00:00 +0000</pubDate><guid>https://glp1decode.com/zh/posts/zepbound-tirzepatide-weight-loss-2026/</guid><description>Zepbound（tirzepatide）是最新获批用于减肥的 GLP-1/GIP 双受体激动剂。我们详细解读 SURMOUNT 试验结果、真实世界效果、副作用，以及它与 Wegovy 和 Mounjaro 的比较。</description></item></channel></rss>